Clinical Commander

Back to dossier
cardio.cardiogenic-shock.covid-myocarditis.v1PRODUCTION
cardio.cardiogenic-shock.covid-myocarditis.v1

Cardiogenic shock — COVID-19-associated myocarditis (infection or post-mRNA-vaccine)

cardiologyacuteadult
Hard-required inputs
0 / 20
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm COVID-associated myocarditis etiology — recent infection (PCR+ within 4 wks) OR recent mRNA vaccination (within 2-7 d, especially young male <30); biventricular dysfunction, no obstructive CAD, troponin elevation; identify phenotype (acute infection vs post-vaccine vs MIS-A overlap) which drives diagnostic + treatment pathway

Inputs
2
Actions
0
Advance rule
Set
Advance when

COVID-myocarditis confirmed and phenotype hypothesis stated

Patient inputs (22)

Mandatory rule-out of obstructive CAD when shock with troponin elevation; especially important in older adults; clean coronaries support myocarditis differential

Lake Louise Criteria 2018 (Ferreira PMID 30025572); vaccine myocarditis often shows inferolateral mid-myocardial LGE per Daniels Circulation 2021

Age stratifies vaccine myocarditis risk (peak 16-29 yo male) vs acute COVID severity (older adults with comorbidities at higher risk)

Vaccine-associated myocarditis predominantly young males; informs phenotype probability

Tachyarrhythmia possible; transient AV block reported in vaccine cases

End-organ damage marker + dose adjustment + gadolinium safety screen for CMR

mRNA vaccine within 2-7 days, dose number, manufacturer (Pfizer / Moderna) → vaccine-associated myocarditis differential

Active or recent (within 4 wks) SARS-CoV-2 infection by PCR, antigen, or serology → acute infection phenotype

Concurrent COVID respiratory failure may co-exist in acute infection phenotype; informs ventilation + dexamethasone candidacy

Markedly elevated typical; trend correlates with severity; persistent elevation suggests ongoing myocyte injury

Acute HF marker; trend tracks recovery

Cytokine storm marker; informs tocilizumab candidacy in acute COVID phenotype

Cytokine storm / hyperinflammation marker; MIS-A diagnostic criterion

COVID-associated VTE risk screening; baseline for anticoagulation decision

Lymphopenia in COVID; eosinophilia argues against COVID etiology and toward eosinophilic myocarditis

Establishes active acute infection vs prior; informs antiviral candidacy (nirmatrelvir-ritonavir if within 5 d)

Biventricular dysfunction; effusion screen; no regional wall motion crossing single coronary territory

Diffuse ST/T-wave changes; PR depression if pericarditis overlap; AV block uncommon (more typical of giant cell)

SCAI 2022 staging baseline; gates vasopressor escalation

SCAI 2022 staging + CardShock prognostication (Harjola EHJ 2015 PMID 26333869)

Anti-N supports prior infection (not vaccine-induced); anti-S confounded by vaccination; helps differentiate acute infection vs post-vaccine phenotype

Elevated >40 pg/mL supports cytokine storm and tocilizumab candidacy per REMAP-CAP / RECOVERY

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningmis_a_overlap_with_acute_covid_myocarditis
    MIS-A criteria met (fever + ≥2 organ involvement + lab inflammation + recent SARS-CoV-2 + no alternative diagnosis) per Belay MMWR 2021 — high-mortality multisystem inflammatory syndrome with cardiac involvement; emergent IVIG + glucocorticoids
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningfulminant_mrna_vaccine_associated_myocarditis_pattern
    Fulminant presentation in mRNA vaccine-associated myocarditis (rare; usually post-dose 2 in young males <30) — sustained VT/VF, severe LV dysfunction, shock physiology; escalate as for any fulminant myocarditis (NOT mild NSAID/colchicine pathway)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningmcs_bridge_to_recovery_in_fulminant_covid_myocarditis
    Refractory CS in fulminant COVID-associated myocarditis — escalate to MCS (IABP / Impella / VA-ECMO) early; recovery is the rule if patient survives initial period (McCarthy NEJM 2000 PMID 10717012); ELSO 2020 ECMO myocarditis registry — 60-70% survival to discharge
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecovid_cytokine_storm_with_il6_elevation
    Cytokine storm pattern in acute COVID myocarditis — markedly elevated CRP (>75) + IL-6 (>40 pg/mL) + ferritin + d-dimer + multi-organ involvement; tocilizumab candidacy
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveretransient_av_block_in_covid_myocarditis
    New transient or sustained AV block in COVID-associated myocarditis — uncommon but described; if persistent / high-grade consider giant cell differential and EMB; transvenous pacemaker if symptomatic
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

COVID-associated myocarditis CS — supportive + cautious inotrope + early MCS bridge to recovery + phenotype-specific (cytokine storm therapy for acute infection; NSAID + colchicine for vaccine-associated mild)
axis: covid_myocarditis_cs_phenotype
Selected axis "COVID-associated myocarditis CS — supportive + cautious inotrope + early MCS bridge to recovery + phenotype-specific (cytokine storm therapy for acute infection; NSAID + colchicine for vaccine-associated mild)" by default fallback (first axis)
  • norepinephrine
    first line
    vasopressor_alpha
    0.05–0.5 µg/kg/min titrate MAP ≥65 • IV • continuous
    triggers: covid_myocarditis_with_sbp_lt_90, cs_scai_c_or_higher
    SOAP-II PMID 20200382 — NE first-line in CS
    rxcui 7512
  • dobutamine
    second line
    inotrope_beta1
    2.5 µg/kg/min CAUTIOUS titration; AVOID in ventricular electrical storm • IV • continuous
    triggers: low_cardiac_output_despite_NE, no_active_VT_or_VF
    DOREMI PMID 33704937; CAUTION in inflamed myocardium — escalate to MCS rather than higher inotrope doses
    rxcui 3616
  • tocilizumab
    add on
    il6_receptor_antagonist
    8 mg/kg IV (max 800 mg) single dose, may repeat × 1 • IV • single dose
    triggers: acute_covid_myocarditis_with_cytokine_storm, crp_gt_75_or_il_6_gt_40
    REMAP-CAP PMID 33631065 + RECOVERY tocilizumab arm PMID 33933206 — IL-6 receptor blockade in COVID hyperinflammation
    rxcui 612865
  • dexamethasone
    comorbidity specific
    corticosteroid_systemic
    6 mg IV/PO daily × up to 10 days • IV/PO • daily
    triggers: concurrent_covid_respiratory_failure_o2_or_vent
    RECOVERY PMID 32678530 — for concurrent COVID respiratory failure ONLY, NOT trial-evidenced for myocardial involvement; do not use solely for myocarditis
    rxcui 3264
  • nirmatrelvir-ritonavir
    comorbidity specific
    covid_protease_inhibitor
    300/100 mg PO BID × 5 days; renal adjust if eGFR 30-60; CI eGFR <30 • PO • BID × 5 d
    triggers: acute_covid_within_5d_symptom_onset, no_qt_prolonging_drugs, egfr_geq_30
    EPIC-HR PMID 35172054 — early antiviral; CHECK extensive drug interactions
    rxcui 2587892
  • ivig
    add on
    immune_globulin_iv
    1-2 g/kg IV total dose (split over 1-2 d) • IV • single course
    triggers: fulminant_covid_myocarditis_uncontrolled_by_supportive, mis_a_with_cardiac_involvement
    Robinson Lancet 2020 + uncontrolled case series; pediatric MIS-C IVIG well-established (Belay MMWR 2021); adult RCT lacking but considered in fulminant + MIS-A
    rxcui 11289
  • aspirin
    first line
    nsaid_cox1_cox2
    650-1000 mg PO TID × 1-2 wk then taper • PO • TID
    triggers: vaccine_associated_myocarditis_mild_no_severe_lv_dysfunction, pericarditis_overlap
    ACC 2022 vaccine myocarditis consensus — NSAID + colchicine for mild vaccine cases; AVOID if fulminant or severe LV dysfunction
    rxcui 1191
  • colchicine
    first line
    colchicine_anti_inflammatory
    0.6 mg PO BID × 3 mo • PO • BID
    triggers: vaccine_associated_myocarditis_mild, myo_pericarditis_overlap
    Imazio CORE/CORP-2 (PMID 24168736) for pericarditis; ACC 2022 vaccine myocarditis consensus
    rxcui 2683
  • enoxaparin
    first line
    lmwh
    40 mg SC daily prophylactic; 1 mg/kg SC q12h therapeutic • SC • daily/q12h
    triggers: covid_myocarditis_admitted, d_dimer_elevated
    CHEST 2020 COVID anticoagulation guidance; high VTE risk in COVID
    rxcui 67108
  • amiodarone
    rescue
    class_iii_antiarrhythmic
    150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min • IV • continuous
    triggers: ventricular_electrical_storm_in_covid_myocarditis, sustained_vt_or_vf
    AHA 2020 ACLS Class IIb for refractory VT/VF; high arrhythmia risk in inflamed myocardium
    rxcui 703

outpatient playbook — drug actions (3)

  1. 1. continue or up-titrate GDMT 4-pillar if persistent EF<40
    lisinopril or sac/val + carvedilol + MRA + SGLT2i • PO • daily/BID
    trigger: Persistent EF<40
    AHA/ACC/HFSA 2022 HF Guideline (PMID 35363499)
  2. 2. AVOID further mRNA vaccine without shared decision
    CDC ACIP guidance • n/a • n/a
    trigger: History of vaccine-associated myocarditis
    CDC ACIP + AHA 2021 — alternative vaccine or deferred dose with shared decision
  3. 3. AVOID NSAIDs lifelong if fulminant phenotype
    do not give • n/a • n/a
    trigger: History of fulminant COVID myocarditis
    ESC 2013

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Acute COVID-19 infection (PCR+ within past 4 weeks) with new acute heart failure + cardiogenic shock physiology — acute COVID myocarditis with CS; Recent mRNA COVID vaccine (Pfizer / Moderna) within 2-7 days + acute chest pain ± dyspnea ± troponin elevation, especially young male <30 — vaccine-associated myocarditis (usually mild but rarely fulminant); Cardiac MRI: T2 edema + LGE (sub-epicardial / mid-myocardial, often inferolateral in vaccine cases) + abnormal native T1/T2 (≥2 of 3 = Lake Louise 2018) + recent COVID exposure or vaccination.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiogenic shock — COVID-19-associated myocarditis (infection or post-mRNA-vaccine)** (cardio.cardiogenic-shock.covid-myocarditis.v1).
Scope: Confirm COVID-associated myocarditis etiology — recent infection (PCR+ within 4 wks) OR recent mRNA vaccination (within 2-7 d, especially young male <30); biventricular dysfunction, no obstructive CAD, troponin elevation; identify phenotype (acute infection vs post-vaccine vs MIS-A overlap) which drives diagnostic + treatment pathway

No severity triggers fired against current inputs.

Plan

Regimen axis: **COVID-associated myocarditis CS — supportive + cautious inotrope + early MCS bridge to recovery + phenotype-specific (cytokine storm therapy for acute infection; NSAID + colchicine for vaccine-associated mild)**.
1. norepinephrine 0.05–0.5 µg/kg/min titrate MAP ≥65 IV continuous (vasopressor_alpha, first line) — SOAP-II PMID 20200382 — NE first-line in CS
2. dobutamine 2.5 µg/kg/min CAUTIOUS titration; AVOID in ventricular electrical storm IV continuous (inotrope_beta1, second line) — DOREMI PMID 33704937; CAUTION in inflamed myocardium — escalate to MCS rather than higher inotrope doses
3. tocilizumab 8 mg/kg IV (max 800 mg) single dose, may repeat × 1 IV single dose (il6_receptor_antagonist, add on) — REMAP-CAP PMID 33631065 + RECOVERY tocilizumab arm PMID 33933206 — IL-6 receptor blockade in COVID hyperinflammation
4. dexamethasone 6 mg IV/PO daily × up to 10 days IV/PO daily (corticosteroid_systemic, comorbidity specific) — RECOVERY PMID 32678530 — for concurrent COVID respiratory failure ONLY, NOT trial-evidenced for myocardial involvement; do not use solely for myocarditis
5. nirmatrelvir-ritonavir 300/100 mg PO BID × 5 days; renal adjust if eGFR 30-60; CI eGFR <30 PO BID × 5 d (covid_protease_inhibitor, comorbidity specific) — EPIC-HR PMID 35172054 — early antiviral; CHECK extensive drug interactions
6. ivig 1-2 g/kg IV total dose (split over 1-2 d) IV single course (immune_globulin_iv, add on) — Robinson Lancet 2020 + uncontrolled case series; pediatric MIS-C IVIG well-established (Belay MMWR 2021); adult RCT lacking but considered in fulminant + MIS-A
7. aspirin 650-1000 mg PO TID × 1-2 wk then taper PO TID (nsaid_cox1_cox2, first line) — ACC 2022 vaccine myocarditis consensus — NSAID + colchicine for mild vaccine cases; AVOID if fulminant or severe LV dysfunction
8. colchicine 0.6 mg PO BID × 3 mo PO BID (colchicine_anti_inflammatory, first line) — Imazio CORE/CORP-2 (PMID 24168736) for pericarditis; ACC 2022 vaccine myocarditis consensus
9. enoxaparin 40 mg SC daily prophylactic; 1 mg/kg SC q12h therapeutic SC daily/q12h (lmwh, first line) — CHEST 2020 COVID anticoagulation guidance; high VTE risk in COVID
10. amiodarone 150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min IV continuous (class_iii_antiarrhythmic, rescue) — AHA 2020 ACLS Class IIb for refractory VT/VF; high arrhythmia risk in inflamed myocardium

Setting playbook (outpatient) — 4-8 wk recovery echo + CMR — confirm LV recovery (typical for vaccine-associated and acute viral); long-term GDMT if persistent HFrEF; EP follow-up for ICD eligibility; activity restriction × 3-6 mo per Drezner JACC 2022; vaccine continuation per CDC ACIP shared decision (alternative vaccine considered after vaccine-associated myocarditis)
11. continue or up-titrate GDMT 4-pillar if persistent EF<40 lisinopril or sac/val + carvedilol + MRA + SGLT2i PO daily/BID — Persistent EF<40 (AHA/ACC/HFSA 2022 HF Guideline (PMID 35363499))
12. AVOID further mRNA vaccine without shared decision CDC ACIP guidance n/a n/a — History of vaccine-associated myocarditis (CDC ACIP + AHA 2021 — alternative vaccine or deferred dose with shared decision)
13. AVOID NSAIDs lifelong if fulminant phenotype do not give n/a n/a — History of fulminant COVID myocarditis (ESC 2013)

Non-pharmacologic actions:
- No competitive sports × 3-6 mo per AHA 2015 / ESC 2020 / Drezner JACC 2022
- Cardiac rehab if persistent LV dysfunction
- EP referral for ICD eligibility per AHA 2017 VA/SCD guideline
- Transplant evaluation if persistent severe LV dysfunction beyond 6 mo

AVOID / contraindication checks:
- Nsaids_AVOID_in_fulminant_covid_myocarditis (worsen myocarditis per ESC 2013)
- Nsaids_PERMITTED_in_mild_vaccine_associated_myocarditis (ACC 2022; usually myo pericardial)
- Dexamethasone_NOT_for_myocardial_involvement_alone (RECOVERY benefit was respiratory; no cardiac trial)
- Nirmatrelvir ritonavir_extensive_drug_interactions (CYP3A4; check QT prolonging agents, amiodarone, statins)
- Nirmatrelvir ritonavir_CI_egfr_lt_30 (drug label)
- Tocilizumab_avoid_active_bacterial_or_fungal_infection (immunosuppression)
- High_dose_dobutamine_minimize_in_inflamed_myocardium (arrhythmia risk; escalate to MCS)
- Ivig_caution_thrombosis_aki_anaphylaxis (premedicate; slow infusion)
- Gadolinium_caution_if_egfr_lt_30 (NSF risk; group II macrocyclic agents safer)

Monitoring

Regimen monitoring:
- arterial line continuous BP (ACC/AHA 2022 Class I)
- central venous access (ACC/AHA 2022)
- lactate q1-2h (CardShock, Harjola EHJ 2015)
- UOP hourly (SCAI 2019 end-organ perfusion marker)
- serial echo q24h for recovery trajectory (McCarthy NEJM 2000)
- continuous telemetry for arrhythmia (high VT/VF risk in inflamed myocardium)
- daily troponin and bnp (trend tracks recovery)
- daily crp ferritin il6 if cytokine storm therapy (response monitoring)
- d dimer trend for vte surveillance (COVID hypercoagulability)
- tocilizumab pre screen for TB HBV HCV (per drug label)

Setting (outpatient) monitoring:
- Echo at 6 mo and 12 mo
- CMR at 6 mo if persistent LGE for arrhythmic risk surveillance

Follow-up plan: Repeat echo + CMR at 4-8 wks for recovery trajectory; cardiac rehab; GDMT 4-pillar if persistent HFrEF; EP follow-up for ICD eligibility; activity restriction × 3-6 mo per AHA 2015 / ESC 2020 sports cardiology + Drezner JACC 2022; vaccine continuation shared decision per CDC ACIP
- Close-out criterion: Recovery echo, CMR, GDMT plan, ICD timeline, vaccine plan booked

Monitoring phase: A-line, central line, lactate clearance, urine output; continuous telemetry; serial echo q24h for LV recovery trajectory; daily troponin and BNP; serial ECG for AV block; daily CRP / ferritin / IL-6 if cytokine storm therapy

Disposition

Current setting: outpatient — 4-8 wk recovery echo + CMR — confirm LV recovery (typical for vaccine-associated and acute viral); long-term GDMT if persistent HFrEF; EP follow-up for ICD eligibility; activity restriction × 3-6 mo per Drezner JACC 2022; vaccine continuation per CDC ACIP shared decision (alternative vaccine considered after vaccine-associated myocarditis)

Disposition criteria:
- Complete recovery (EF ≥55 + symptom-free + CMR resolved) → routine surveillance only
- Persistent HFrEF → long-term cross-link to cardio.hfref.core.v1 / cardio.hf.core.v1

Escalation triggers (move to higher acuity):
- Sustained VT / syncope → EP urgent consult; consider catheter ablation; ICD
- Persistent severe LV dysfunction → transplant evaluation
- Recurrent myocarditis → repeat workup; reconsider underlying etiology

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] MIS-A criteria met (fever + ≥2 organ involvement + lab inflammation + recent SARS-CoV-2 + no alternative diagnosis) per Belay MMWR 2021 — high-mortality multisystem inflammatory syndrome with cardiac involvement; emergent IVIG + glucocorticoids
- [LIFE_THREATENING] Fulminant presentation in mRNA vaccine-associated myocarditis (rare; usually post-dose 2 in young males <30) — sustained VT/VF, severe LV dysfunction, shock physiology; escalate as for any fulminant myocarditis (NOT mild NSAID/colchicine pathway)
- [LIFE_THREATENING] Refractory CS in fulminant COVID-associated myocarditis — escalate to MCS (IABP / Impella / VA-ECMO) early; recovery is the rule if patient survives initial period (McCarthy NEJM 2000 PMID 10717012); ELSO 2020 ECMO myocarditis registry — 60-70% survival to discharge

Citations

- AHA 2022 cardiovascular manifestations of COVID-19 (Gluckman PMID 35403432); ACC 2022 expert consensus on athletes post-COVID; Patone Nat Med 2022 mRNA vaccine-associated myocarditis (PMID 35115708); Caforio ESC 2013 myocarditis position paper (PMID 23824828); Tschöpe AHA 2020 myocarditis scientific statement (PMID 32200645); Ferreira JACC 2018 Lake Louise Criteria 2018 (PMID 30025572) [PMID:35403432](https://pubmed.ncbi.nlm.nih.gov/35403432/)
- Cited evidence (PMID 35115708) [PMID:35115708](https://pubmed.ncbi.nlm.nih.gov/35115708/)
- Cited evidence (PMID 23824828) [PMID:23824828](https://pubmed.ncbi.nlm.nih.gov/23824828/)
- Cited evidence (PMID 32200645) [PMID:32200645](https://pubmed.ncbi.nlm.nih.gov/32200645/)
- Cited evidence (PMID 30025572) [PMID:30025572](https://pubmed.ncbi.nlm.nih.gov/30025572/)

Last reconciled with current guidelines: 2026-05-15.
References
  • AHA 2022 cardiovascular manifestations of COVID-19 (Gluckman PMID 35403432); ACC 2022 expert consensus on athletes post-COVID; Patone Nat Med 2022 mRNA vaccine-associated myocarditis (PMID 35115708); Caforio ESC 2013 myocarditis position paper (PMID 23824828); Tschöpe AHA 2020 myocarditis scientific statement (PMID 32200645); Ferreira JACC 2018 Lake Louise Criteria 2018 (PMID 30025572) — PMID:35403432
  • Cited evidence (PMID 35115708) — PMID:35115708
  • Cited evidence (PMID 23824828) — PMID:23824828
  • Cited evidence (PMID 32200645) — PMID:32200645
  • Cited evidence (PMID 30025572) — PMID:30025572